David Harris
Founder and Chief Executive Officer @Chi
Signup · Get unlimited contacts
WORK HISTORY
Founder and Chief Executive Officer @Chi
Cambridge, GB
CHI has three DPI technologies:i) Quattrii - a high payload platform, suitable for 50 mg+ii) aeolus - a pressure-amplified platform, suitable for 5 - 50 Occorix - an active DPI platform, suitable for API-only formulations, micronised or engineered.
EDUCATION
The University of Sheffield
Bachelor of Science (BSc hons), Physics
SKILLS
ABOUT DAVID HARRIS
In 2018 we founded Cambridge Healthcare Innovations to develop high performance, novel inhalation technologies to deliver new molecules to the lung. Our current interests focus around the future of inhaled medicine, and we are building a strong team and capabilities to design, develop and test devices that will provide the performance and consistency that is required for these new molecules.Our dry powder inhaler (DPI) technologies are purposefully designed to be as inclusive as possible. Patients with compromised lung function - who would typically be prescribed a pressurised metered dose inhaler (pMDI) with a holding chamber (spacer)- will be able to use our DPIs as effectively as patients with perfectly healthy lung function. This is is something that the industry and patients desperately need. The current state of affairs in which decades-old technology is repurposed to deliver new, state-of-the-art molecules does very little to improve things - particularly for the patient. We\'re changing that.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.